Subcutaneous epcoritamab combined with rituximab plus lenalidomide for the treatment of patients with relapsed or refractory follicular lymphoma: phase 1/2 trial update
Lorenzo, F. Sirpa, L. Wahlin, B. E. Marcel, N. Christensen, J. H. De, V. S. Harald, H. Aqeel, A. Wang, L. W.
Lorenzo, F.
Sirpa, L.
Wahlin, B. E.
Marcel, N.
Christensen, J. H.
De, V. S.
Harald, H.
Aqeel, A.
Wang, L. W.
Citations
Altmetric:
Abstract
Description
Date
2022
Publisher
Collections
Keywords
Type
Meetings and Proceedings
Citation
Lorenzo F, Sirpa L, Wahlin BE, Marcel N, Christensen JH, De VS, et al. Subcutaneous Epcoritamab Combined With Rituximab plus Lenalidomide for the Treatment of Patients with Relapsed or Refractory Follicular Lymphoma: Phase 1/2 Trial Update. American journal of hematology. 2022 Oct;97:S31-S. PubMed PMID: WOS:000866743000051.